The Power to Get It Right
Move Beyond Suspicion to Precision
Even the best clinical diagnosis for neurodegenerative disorders is wrong 33-44% of the time.
SAAmplify™-αSYN is the first clinically available, validated test that detects pathological α-synuclein with autopsy-confirmed accuracy—bringing unprecedented biological clarity to the diagnosis of diseases like Parkinson’s, Lewy body dementia, and Alzheimer’s.
The Limitations of Yesterday
- Treatment decisions based on "probable" diagnosis
- 2-3 years average time in diagnostic odyssey
- Clinical diagnosis contradicted by autopsy in up to 30% of cases
- Up to 50% of Alzheimer's patients also have Lewy body pathology
- Most neurodegenerative disorders involve mixed pathologies, not single diseases
For decades, physicians have been forced to diagnose based on symptoms, missing the complex reality of mixed pathologies that define most neurodegenerative disorders.
The Certainty of Today
- Only validated test for detecting misfolded α-synuclein in CSF
- Used in over 20,000 samples to date
- Autopsy-confirmed accuracy
- Treatment decisions guided by biological evidence
SAAmplify-ɑSYN reveals what symptoms can't tell you – the actual biology driving neurodegenerative disease.
We have the real possibility to impact the life of millions and millions of people if we can identify the disease before it damages the brain.
Peer-Reviewed Proof, Not Just Claims
While others claim accuracy, we back it up with proof: Our technology is supported by 400+ autopsy confirmations, 1,200+ scientific publications, and analysis of over 20,000 samples. Our evidence-based approach delivers certainty where it matters most.
Scientific Paper
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease
Scientific Paper
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease
Scientific Paper
LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Where Research Meets Results
Our research partnerships have generated unprecedented insights into neurodegenerative disease biology. Every collaboration brings us closer to understanding and addressing these complex conditions.
The Power to Know Starts Here
Whether you're a clinician seeking biological insights for your patients, a researcher advancing neurodegenerative science, or a patient navigating a complex diagnostic journey, the SAAmplify-ɑSYN seed amplification assay delivers unparalleled certainty by detecting the underlying biology of these conditions.
Understanding the biological basis of neurodegenerative symptoms provides clarity for your healthcare journey.
Our test detects ɑ-synuclein pathology that underlies several conditions including Parkinson's, Lewy body dementia and atypical Alzheimer's.
✓ Learn about the biology behind neurodegenerative symptoms
✓ Understand what ɑ-synuclein testing reveals
✓ Access resources to better navigate your diagnostic journey
Stop relying on symptoms and access the biology of neurodegenerative diseases.
The SAAmplify-ɑSYN test detects ɑ-synuclein pathology with autopsy-confirmed accuracy for more definitive diagnosis across movement and cognitive disorders.
✓ Detect synucleinopathies before symptoms progress
✓ 100% correlation with autopsy confirmation
✓ Identify mixed pathologies for improved care
Accelerate your clinical trials with the gold standard for ɑ-synuclein detection.
Our FDA-supported seed amplification assay helps you stratify patients, monitor treatment efficacy, and develop targeted therapeutics with greater precision.
✓ FDA letter of support as a drug development tool
✓ Partner with the exclusive source of SAA technology
✓ Access expertise from 400+ autopsy confirmations
Get in the Know
Bring biological certainty to your diagnosis with Amprion's SAAmplify-ɑSYN test. Order your shipping kits today and help move your patient beyond a probable diagnosis.
